Compare CarMax, Inc (KMX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? CarMax, Inc trades at $58.03 (market cap $8.34B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 15.9× CarMax, Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| KMX | VRTX | |
|---|---|---|
Market Cap | $8.34B | $132.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $62.17 | $529.65 |
52-Week Low | $30.88 | $376.62 |
Enterprise Value | $26.85B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $58.18, up 0.21% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance, beating expectations in Q3 2025 and Q1 2026 but missing in Q2 2025. Revenue has declined from $31.9B in 2022 to $26.35B in 2025, while net income margin improved slightly to 1.89%. Recent news includes partnerships to enhance customer experience and ongoing legal investigations into fiduciary duties.
Outlook is cautious with a consensus price target of $53.09 below the current price, indicating potential downside. Opportunities lie in operational improvements and AI integrations, but risks include high debt, competitive pressures, and legal scrutiny. Analyst sentiment is neutral with 68.58% hold ratings, suggesting wait-and-see approach amid volatility.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
